Ex-Teva Executive To Steer Dr Reddy’s As COO
Executive Summary
Erez Israeli, ex-Teva long-timer, is set to take over as Dr Reddy’s chief operating officer and global head of the generics and PSAI (pharmaceuticals services and active ingredients) businesses. Israeli’s appointment comes at a time when the Indian firm tackles multiple operational challenges, including compliance issues at its plants.
You may also be interested in...
Big Cost Cuts At Dr Reddy’s, US Big Ticket Launch Progress Is Key
Massive reorganization efforts are underway at Dr Reddy’s as it recalibrates costs; an antibiotics site is expected to be sold soon as part of these efforts and more may be in store. Management commentary was, however, upbeat around the growth outlook for the US business, with visibility of 15-20 launches in FY 2019.
Bad News Teva Really Doesn't Need: A Potential Delay For Fremanezumab
One of Teva's few bright spots is its leading position in the big new commercial opportunity for migraine, but its CGRP drug fremanezumab could now be delayed by an issue at third-party manufacturer Celltrion.
Dr Reddy’s Pins Hopes On Complex Drugs Pipeline Amid Weak Q3
Dr Reddy’s Laboratories is betting on complex product launches to power an improvement in its bottom line after reporting a 29% drop in quarterly net profit, hit by price erosion in its main US market.